首页> 外文期刊>Cureus. >Incidence and Outcomes of Acute Kidney Injury Requiring Renal Replacement Therapy in Patients on Percutaneous Mechanical Circulatory Support with Impella-CP for Cardiogenic Shock
【24h】

Incidence and Outcomes of Acute Kidney Injury Requiring Renal Replacement Therapy in Patients on Percutaneous Mechanical Circulatory Support with Impella-CP for Cardiogenic Shock

机译:急性肾损伤的发病率和结果需要肾脏替代疗法患者经皮机械循环载体与Impella-CP进行心源性休克

获取原文
           

摘要

Background: Acute kidney injury (AKI) complicating cardiogenic shock is associated with increased mortality. We hypothesize that renal replacement therapy (RRT)?improves survival in cardiogenic shock supported by Impella-CP (Abiomed, Danvers, MA) complicated by AKI. Methods: A retrospective chart review identified 34 patients on Impella-CP for cardiogenic shock between January 2015 and December 2017. AKI was defined as an increase in serum creatinine≥0.3 mg/dL from baseline. Three groups were analyzed: AKI plus RRT, AKI minus RRT, and no AKI. Pre-existing dialysis patients were excluded. The only indication for RRT was AKI not responding to diuretics. Thirty-day mortality was analyzed. Results: There were 13 patients with no AKI, 9 with AKI plus RRT groups, and 12 with AKI minus RRT. Thirty-day mortality was similar between no AKI and AKI plus RRT groups [30.8% (4/13) vs.22.2% (2/9), p=0.48; relative risk [RR] 2.25 (95% confidence interval [CI] 0.22-22.1)]. Thirty-day mortality was higher in AKI minus RRT group compared to the no AKI group [75.0% (9/12) vs. 30.8% (4/13); p=0.03; RR 6.75 (95% CI 1.16-39.2)]. Conclusion: In cardiogenic shock patients on Impella-CP, AKI minus RRT is associated with a higher 30-day mortality compared to patients without AKI and/or patients with AKI plus RRT. Short-term mortality may improve in cardiogenic shock patients with AKI who are treated with RRT.
机译:背景:急性肾脏损伤(AKI)复杂的心源性休克与增加的死亡率增加有关。我们假设肾替代疗法(RRT)?通过AKI复杂的Impla-CP(附着,Danvers,MA)支持的心底生休克存活率提高了AKI。方法:回顾性图表审查确定了34名Impella-CP患者2015年1月和2017年12月之间的心绞痛休克。AKI被定义为基线的血清肌酐≥0.3mg/ dl增加。分析了三组:AKI Plus RRT,AKI减去RRT,没有AKI。预先存在的透析患者被排除在外。 RRT的唯一迹象是AKI没有响应利尿剂。分析了30天的死亡率。结果:13名患者没有AKI,9例,带有AKI PLUS RRT组,12名带有AKI减去RRT。在没有aki和aki plus rrt组之间的三十天死亡率相似[30.8%(4/13)vs.22.2%(2/9),p = 0.48;相对风险[RR] 2.25(95%置信区间[CI] 0.22-22.1)]。与NO AKI集团相比,AKI减去RRT组的30天死亡率较高[75.0%(9/12)与30.8%(4/13); p = 0.03; RR 6.75(95%CI 1.16-39.2)]。结论:在Impella-CP上的心肌休克患者中,与没有AKI和/或AKI Plus RRT患者的患者相比,AKI减去RRT与30天的患者相比有关。短期死亡率可能改善患有RRT治疗的AKI的心底生休克患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号